|This message contains images. If you don't see images, click here to view.|
here to advertise in this news brief.
OPTN/UNOS Board approves significant revisions to deceased donor kidney allocation policy
U.S. Department of Health & Human Services
The OPTN/UNOS Board of Directors, meeting June 24 and 25, approved substantial amendments to OPTN policy for deceased donor kidney allocation. The policy will maintain access to kidney transplantation for all groups of candidates while seeking to improve outcomes for kidney transplant recipients, increase the years recipients may have a functioning transplant and increase utilization of available kidneys. The implementation date of the policy was not immediately established but is expected to occur in 2014.
Chimera needs you!
ASTS' member magazine, Chimera, showcases members and their activities. We'd love to spread the word about your latest career move, hire, or award in our "People and Places" section. We also offer the chance to profile your transplant program in "Across the Field" with a short write-up and photo of your team. Please consider taking advantage of this easy way to gain recognition for your hard work! The summer issue is scheduled to come out in August, so please submit your information to email@example.com by July 5.
The calendar is filling up
Check out everything that's happening this summer and fall on the ASTS Calendar of Events. Here are a few of the recent additions:
ASTS also offers opportunities for professional development; check out ASTS.org/education for the latest offerings.
- Stem Cells in Translation, Sept. 15-18, 2013, Florence, Italy
- World Congress of Surgery, Obstetrics, Trauma and Anesthesia (WCSOTA), Oct. 16-17, 2013, Port of Spain, Trinidad and Tobago
- The Americas Hepato-Pancreato Biliary Association 2014 Conference, Feb. 19 – 23, 2014, Miami Beach, Florida
HHS releases new guideline to reduce disease transmission through organ transplantation
Infection Control Today
The U.S. Department of Health and Human Services (HHS) has released a new guideline to improve patient safety by reducing unexpected disease transmission through organ transplantation. This guideline updates the 1994 U.S. Public Health Service (PHS) guideline for preventing transmission of human immunodeficiency virus (HIV) through organ transplantation and adds guidance for reducing unexpected transmission of hepatitis B virus (HBV) and hepatitis C virus (HCV) through organ transplants.
Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients
Pediatric Transplantation (login required)
The aim of this study was to assess the immunogenicity of a vaccine against this virus in a prospective cohort of transplanted pediatric patients without previous influenza infection who received one dose of MF59®-adjuvanted pandemic H1N1/2009 vaccine. Seventeen patients who were being regularly followed up at the Outpatient Clinic of the Children's Transplant Unit (liver and kidney transplantation) in Hospital Universitari Vall d'Hebron (Barcelona) were included. Seroconversion was demonstrated in 15 of 17 (88.2 percent) vaccinated children. There were no rejection episodes or major adverse events. The MF59®-adjuvanted pandemic H1N1/2009 vaccine was safe and elicited an adequate response.
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation
Liver Transplantation (login required)
The safety, efficacy and effect on immunosuppression levels of telaprevir (TVR) or boceprevir (BOC) in combination with peginterferon (PEG-IFN) and ribavirin (RBV) in recipients of liver transplantation (LT) with hepatitis C virus (HCV) genotype 1 have not been defined.
Trial: Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation
Liver Transplantation (login required)
Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation. In this prospective, open-label, multicenter study, patients undergoing transplantation from July 2005 to June 2007 who were maintained on MMF/CNI were randomized 4 to 12 weeks after transplantation to receive MMF/SRL (n = 148) or continue MMF/CNI (n = 145) and included in the intent-to-treat population.
African-Americans on Medicaid less likely to receive living kidney transplants
Nephrology News & Issues
African-Americans with Medicaid as their primary insurance were less likely to receive a living kidney transplant (LKT) than patients with private insurance, according to a new study by researchers at Wake Forest Baptist Medical Center. The study is published in an online edition of Clinical Transplantation.
Cyclosporine versus everolimus: Effects on the glomerulus
Clinical Transplantation (login required)
Inhibitors of the mammalian target of rapamycin (mTOR) have been associated with proteinuria. In a recent study, researchers studied the development of proteinuria in renal transplant recipients (RTR) treated with the mTOR inhibitor everolimus in comparison with a calcineurin inhibitor. They related the presence of proteinuria to histopathological glomerular findings in two-year protocol biopsies.
Missed our previous issues? See which articles your colleagues read most.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063